PMID- 24728333
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20221207
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 74
IP  - 9
DP  - 2015 Sep
TI  - Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of 
      incident gout: a population-based case-control study.
PG  - 1651-8
LID - 10.1136/annrheumdis-2014-205337 [doi]
AB  - OBJECTIVE: The aim of this study was to explore the risk of incident gout in 
      patients with type 2 diabetes mellitus (T2DM) in association with diabetes 
      duration, diabetes severity and antidiabetic drug treatment. METHODS: We 
      conducted a case-control study in patients with T2DM using the UK-based Clinical 
      Practice Research Datalink (CPRD). We identified case patients aged >/=18 years 
      with an incident diagnosis of gout between 1990 and 2012. We matched to each case 
      patient one gout-free control patient. We used conditional logistic regression 
      analysis to calculate adjusted ORs (adj. ORs) with 95% CIs and adjusted our 
      analyses for important potential confounders. RESULTS: The study encompassed 7536 
      T2DM cases with a first-time diagnosis of gout. Compared to a diabetes duration 
      <1 year, prolonged diabetes duration (1-3, 3-6, 7-9 and >/=10 years) was associated 
      with decreased adj. ORs of 0.91 (95% CI 0.79 to 1.04), 0.76 (95% CI 0.67 to 
      0.86), 0.70 (95% CI 0.61 to 0.86), and 0.58 (95% CI 0.51 to 0.66), respectively. 
      Compared to a reference A1C level of <7%, the risk estimates of increasing A1C 
      levels (7.0-7.9, 8.0-8.9 and >/=9%) steadily decreased with adj. ORs of 0.79 (95% 
      CI 0.72 to 0.86), 0.63 (95% CI 0.55 to 0.72), and 0.46 (95% CI 0.40 to 0.53), 
      respectively. Neither use of insulin, metformin, nor sulfonylureas was associated 
      with an altered risk of incident gout. CONCLUSIONS: Increased A1C levels, but not 
      use of antidiabetic drugs, was associated with a decreased risk of incident gout 
      among patients with T2DM.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Bruderer, Saskia G
AU  - Bruderer SG
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
      Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 
      Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.
FAU - Bodmer, Michael
AU  - Bodmer M
AD  - Division of General Internal Medicine, Bern University Hospital, Inselspital, 
      Bern, Switzerland.
FAU - Jick, Susan S
AU  - Jick SS
AD  - Boston Collaborative Drug Surveillance Program, Boston University School of 
      Public Health, Lexington, Massachusetts, USA.
FAU - Meier, Christoph R
AU  - Meier CR
AD  - Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
      Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland 
      Hospital Pharmacy, University Hospital Basel, Basel, Switzerland Boston 
      Collaborative Drug Surveillance Program, Boston University School of Public 
      Health, Lexington, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140412
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/drug therapy/*epidemiology/metabolism
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Gout/*epidemiology
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
OTO - NOTNLM
OT  - Arthritis
OT  - Epidemiology
OT  - Gout
EDAT- 2014/04/15 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/04/15 06:00
PHST- 2014/02/03 00:00 [received]
PHST- 2014/03/22 00:00 [accepted]
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - annrheumdis-2014-205337 [pii]
AID - 10.1136/annrheumdis-2014-205337 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2015 Sep;74(9):1651-8. doi: 10.1136/annrheumdis-2014-205337. Epub 
      2014 Apr 12.